Brief: Abliva Says Intends To Start A Pivotal Kl1333 Study Second Half 2021

Abliva AB

09/09/2020 21:30

Sept 9 (Reuters) - Abliva AB  ABLI.ST :
    * ABLIVA INTENDS TO START A PIVOTAL KL1333 STUDY SECOND HALF
2021
    * DECIDED TO ACCELERATE KL1333 CLINICAL PROGRAM, WITH
INTENTION TO
START A PIVOTAL PHASE II/III CLINICAL STUDY, DURING H2 2021
    * DECISION FOLLOWS RECENT POSITIVE FEEDBACK RECEIVED FROM US
FOOD
AND DRUG ADMINISTRATION
    * LONG-TERM TOXICOLOGY STUDIES WILL BE INITIATED THAT WILL
RUN IN
PARALLEL WITH PIVOTAL STUDY IN AGREEMENT WITH FDA

Source text for Eikon:  ID:nNDLbr5YDm 
Further company coverage:  ABLI.ST 

 ((Reuters.Briefs@thomsonreuters.com;))